ArticleiScience2022

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.

Marius Külp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.